Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Switches Between Ustekinumab and ABP 654 in Plaque Psoriasis
NCT04761627Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2021
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in plaque psoriasis (2 arms), sponsored by Amgen. Primary endpoints: Area Under the Plasma Concentration Time Curve Over the Dosing Interval and Maximum Observed Serum Concentration. Started Mar 2021; status: completed.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04761627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04761627.